CytoDyn Inc. (CYDY) Analysts See $-0.07 EPS

March 15, 2018 - By Henry Gaston

 CytoDyn Inc. (CYDY) Analysts See $ 0.07 EPS

Analysts expect CytoDyn Inc. (OTCMKTS:CYDY) to report $-0.07 EPS on April, 12.They anticipate $0.01 EPS change or 16.67 % from last quarter’s $-0.06 EPS. The stock decreased 0.29% or $0.01 during the last trading session, reaching $0.68. About 92,193 shares traded. CytoDyn Inc. (OTCMKTS:CYDY) has 0.00% since March 15, 2017 and is . It has underperformed by 16.70% the S&P500.

CytoDyn Inc., a clinical-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus infection. The company has market cap of $142.06 million. The Company’s lead product under development for HIV infection include PRO 140, a therapeutic anti-viral agent, which is in Phase IIb treatment substitution trial, Phase IIb extension study, Phase IIb/III pivotal trial, and Phase IIb/III investigative trial for HIV; and Phase II trial for graft-versus-host disease. It currently has negative earnings.

More notable recent CytoDyn Inc. (OTCMKTS:CYDY) news were published by: which released: “CytoDyn Is Worth A Look Before Phase 3 HIV Data” on November 20, 2017, also with their article: “CytoDyn Dresses HIV Patients In CCR5 Halloween ‘Mask'” published on October 20, 2017, published: “Cytodyn, Inc. (CYDY) Granted FDA Orphan Drug Designation for PRO 140” on October 05, 2017. More interesting news about CytoDyn Inc. (OTCMKTS:CYDY) were released by: and their article: “CytoDyn to Amend Protocol for PRO 140 Phase 2 Trial in GvHD” published on March 14, 2018 as well as‘s news article titled: “Cytodyn, Inc. (CYDY) Announces Primary Endpoint Achieved in PRO 140 Pivotal …” with publication date: February 20, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: